Trials / Completed
CompletedNCT01290536
Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases
Safety Profile Assessment of TheraSphere® Yttrium-90 Glass Microspheres Used for Treatment of Metastatic Liver Disease From Primary Colorectal, Neuroendocrine, Cholangiocarcinoma, Melanoma, and Breast Cancers Refractory to Chemotherapy: A Pilot Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Nicholas Fidelman, MD · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective pilot study designed to document safety and efficacy of liver-directed therapy for colorectal, neuroendocrine, cholangiocarcinoma, melanoma, and breast cancer metastases to the liver using Yttrium-90 glass microspheres (TheraSphere).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Selective internal radiation therapy to the liver using Yttrium-90 glass microspheres (TheraSphere) | Administration of Yttrium-90 glass microspheres (TheraSphere) into the hepatic artery |
Timeline
- Start date
- 2010-05-01
- Primary completion
- 2013-10-01
- Completion
- 2013-10-01
- First posted
- 2011-02-07
- Last updated
- 2019-03-01
- Results posted
- 2014-12-22
Source: ClinicalTrials.gov record NCT01290536. Inclusion in this directory is not an endorsement.